Related Experiment Video
Updated: Apr 19, 2026
Caspase-3 Activity in the Rat Amygdala Measured by Spectrofluorometry After Myocardial Infarction
Published on: January 12, 2016
Regulation of caspase-3 processing by cIAP2 controls the switch between pro-inflammatory activation and cell death in
E Kavanagh1, J Rodhe1, M A Burguillos1
1Department of Oncology-Pathology, Cancer Centrum Karolinska, R8:03, Karolinska Institutet, Stockholm, Sweden.
Abstract:
The activation of microglia, resident immune cells of the central nervous system, and inflammation-mediated neurotoxicity are typical features of neurodegenerative diseases, for example, Alzheimer's and Parkinson's diseases. An unexpected role of caspase-3, commonly known to have executioner role for apoptosis, was uncovered in the microglia activation process. A central question emerging from this finding is what prevents caspase-3 during the microglia activation from killing those cells? Caspase-3 activation occurs as a two-step process, where the zymogen is first cleaved by upstream caspases, such as caspase-8, to form intermediate, yet still active, p19/p12 complex; thereafter, autocatalytic processing generates the fully mature p17/p12 form of the enzyme. Here, we show that the induction of cellular inhibitor of apoptosis protein 2 (cIAP2) expression upon microglia activation prevents the conversion of caspase-3 p19 subunit to p17 subunit and is responsible for restraining caspase-3 in terms of activity and subcellular localization. We demonstrate that counteracting the repressive effect of cIAP2 on caspase-3 activation, using small interfering RNA targeting cIAP2 or a SMAC mimetic such as the BV6 compound, reduced the pro-inflammatory activation of microglia cells and promoted their death. We propose that the different caspase-3 functions in microglia, and potentially other cell types, reside in the active caspase-3 complexes formed. These results also could indicate cIAP2 as a possible therapeutic target to modulate microglia pro-inflammatory activation and associated neurotoxicity observed in neurodegenerative disorders.
Insights
Cellular inhibitor of apoptosis protein 2 (cIAP2) restrains caspase-3 activity during microglia activation. Inhibiting cIAP2 reduces neuroinflammation and promotes microglia death, offering a therapeutic target for neurodegenerative diseases.
Area of Science:
- Neuroscience
- Immunology
- Cell Biology
Background:
- Microglia activation and neuroinflammation are hallmarks of neurodegenerative diseases like Alzheimer's and Parkinson's.
- Caspase-3, typically an executioner of apoptosis, has an unexpected role in microglia activation.
- A key question is what prevents caspase-3 from inducing cell death during this process.
Purpose of the Study:
- To investigate the mechanism preventing caspase-3-mediated apoptosis during microglia activation.
- To identify the role of cellular inhibitor of apoptosis protein 2 (cIAP2) in regulating caspase-3 activity in microglia.
- To explore the therapeutic potential of targeting cIAP2 for neurodegenerative disorders.
Main Methods:
- Studied the two-step activation process of caspase-3 in microglia.
- Examined the effect of cIAP2 induction on caspase-3 processing and localization.
- Utilized small interfering RNA (siRNA) targeting cIAP2 and a SMAC mimetic (BV6) to counteract cIAP2.
- Assessed changes in microglia pro-inflammatory activation and cell death.
Main Results:
- cIAP2 expression upon microglia activation prevents the conversion of caspase-3's p19 subunit to the mature p17 subunit.
- This inhibition by cIAP2 restrains caspase-3's activity and controls its subcellular localization.
- Blocking cIAP2's effect with siRNA or BV6 reduced pro-inflammatory microglia activation and induced cell death.
- Active caspase-3 complexes appear to dictate its distinct functions in microglia.
Conclusions:
- cIAP2 plays a crucial role in preventing caspase-3-mediated apoptosis in activated microglia.
- Modulating cIAP2 activity could be a therapeutic strategy to control microglia-driven neuroinflammation in neurodegenerative diseases.
- Targeting cIAP2 may offer a novel approach to mitigate neurotoxicity associated with these conditions.
Related Concept Videos
01:24Caspases
01:17The Extrinsic Apoptotic Pathway
01:17Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized...
01:16Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
01:31The Intrinsic Apoptotic Pathway